中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.016 seconds)

    AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE
    1.
    发明申请
    AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE 有权
    预防，改善或治疗退行性疾病的代理人

    公开(公告)号：US20140128475A1

    公开(公告)日：2014-05-08

    申请号：US14154688

    申请日：2014-01-14

    Applicant: ROHTO PHARMACEUTICAL CO., LTD.

    Inventor： Takahiro KUROSE ,  Takayuki MIYANO ,  Mariyo KATO ,  Yoshihiro TAKAI

    IPC: A61K31/121 ,  A61K45/06

    CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K9/0053 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

    Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which(a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

    Abstract translation: （5E，9E，13E）ger anyl ger anyl anyl anyl one one and，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，， 13E）ger anyl ger anyl anyl anyl one one death death death death death death，，，，，death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death 的视网膜细胞，从而从根本上防止，改善或治疗视网膜疾病。

    AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE
    4.
    发明申请
    AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE 审中-公开
    预防，改善或治疗退行性疾病的代理人

    公开(公告)号：US20130303625A1

    公开(公告)日：2013-11-14

    申请号：US13775605

    申请日：2013-02-25

    Applicant: ROHTO PHARMACEUTICAL CO., LTD.

    Inventor： Takahiro KUROSE ,  Takayuki MIYANO ,  Mariyo KATO ,  Yoshihiro TAKAI

    IPC: A61K31/121

    CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K9/0053 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

    Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

    Abstract translation: （5E，9E，13E）ger anyl ger anyl anyl anyl one one and，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，， 13E）ger anyl ger anyl anyl anyl one one death death death death death death，，，，，death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death 的视网膜细胞，从而从根本上防止，改善或治疗视网膜疾病。

    OPHTHALMIC COMPOSITION
    6.
    发明申请
    OPHTHALMIC COMPOSITION 审中-公开
    眼科组合物

    公开(公告)号：US20130303626A1

    公开(公告)日：2013-11-14

    申请号：US13775631

    申请日：2013-02-25

    Applicant: ROHTO PHARMACEUTICAL CO., LTD.

    Inventor： Takayuki MIYANO ,  Takahiro KUROSE

    IPC: A61K47/02

    CPC classification number: A61K47/02 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/121

    Abstract: An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature.

    Abstract translation: 包含香叶基香叶基丙酮和磷酸盐缓冲剂的眼用组合物的优点在于，长期储存期间香叶基香叶基丙酮含量的损失非常小。 这是因为香叶基香叶基丙酮对眼科容器的壁的吸附减少。 包含香叶基香叶基丙酮和磷酸盐缓冲剂的眼用组合物还具有以下优点：香叶基香叶基丙酮对隐形眼镜的吸附少。 此外，即使在低温下储存，包含香叶基香叶基丙酮和磷酸盐缓冲剂的眼用组合物也几乎不变成白色混浊。

    KIT OF OPHTHALMIC COMPOSITION
    7.
    发明申请
    KIT OF OPHTHALMIC COMPOSITION 审中-公开
    手套组成

    公开(公告)号：US20140045948A1

    公开(公告)日：2014-02-13

    申请号：US14056264

    申请日：2013-10-17

    Applicant: ROHTO PHARMACEUTICAL CO., LTD.

    Inventor： Takayuki MIYANO ,  Takahiro KUROSE

    IPC: A61K31/121 ,  A61K9/00

    CPC classification number: A61K31/121 ,  A01N1/0226 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/24 ,  A61K47/26 ,  A61K47/44 ,  A61L12/12 ,  B65D65/38 ,  Y10T428/1397

    Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.

    Abstract translation: 一种眼用组合物试剂盒，其包含容纳含有香叶基香叶基丙酮的眼用组合物的眼用容器，所述眼用容器具有与所述眼用组合物接触的表面，所述表面至少部分或全部由选自以下的容器材料制成：聚烯烃， 丙烯酸树脂，对苯二甲酸酯，聚碳酸酯，聚甲基萜烯，氟树脂和玻璃，眼用组合物试剂盒具有以下优点，即眼用组合物中er牛ger牛儿基丙酮含量的损失或香叶基香叶基丙酮浓度的降低非常小 。

    OPHTHALMIC COMPOSITION
    8.
    发明申请
    OPHTHALMIC COMPOSITION 审中-公开

    公开(公告)号：US20160136275A1

    公开(公告)日：2016-05-19

    申请号：US15007274

    申请日：2016-01-27

    Applicant: ROHTO PHARMACEUTICAL CO., LTD.

    Inventor： Takayuki MIYANO ,  Takahiro KUROSE

    IPC: A61K47/02 ,  A61K9/00 ,  A61K31/121

    CPC classification number: A61K47/02 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/121

    Abstract: An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature.

    OPHTHALMIC COMPOSITION
    9.
    发明申请
    OPHTHALMIC COMPOSITION 审中-公开
    眼科组合物

    公开(公告)号：US20150025154A1

    公开(公告)日：2015-01-22

    申请号：US14506731

    申请日：2014-10-06

    Applicant: ROHTO PHARMACEUTICAL CO., LTD.

    Inventor： Takayuki MIYANO ,  Takahiro KUROSE

    IPC: A61K47/10 ,  A61K9/00 ,  A61K47/14 ,  A61K9/06 ,  A61K47/44 ,  A61K31/121 ,  A61K9/08

    CPC classification number: A61K47/10 ,  A61K9/0048 ,  A61K9/06 ,  A61K9/08 ,  A61K31/121 ,  A61K47/14 ,  A61K47/22 ,  A61K47/44

    Abstract: An ophthalmic composition comprising geranylgeranylacetone and a fat-soluble antioxidant has an advantage that adsorption of geranylgeranylacetone to a wall of a container is remarkably reduced and thereby the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the composition is remarkably reduced. Adsorption of the fat-soluble antioxidant to a wall of a container is also reduced due to combination with geranylgeranylacetone.

    Abstract translation: 包含香叶基香叶基丙酮和脂溶性抗氧化剂的眼用组合物具有显着降低香叶基香叶基丙酮吸附至容器壁的优点，从而显着降低了香叶基香叶基丙酮含量的丧失或香叶基香叶基丙酮浓度的降低。 由于与香叶基香叶基丙酮的组合，脂溶性抗氧化剂对容器壁的吸附也降低。

    OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE
    10.
    发明申请
    OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE 审中-公开
    包含GERANYLGERANYLACETONE的眼科组合物

    公开(公告)号：US20140350119A1

    公开(公告)日：2014-11-27

    申请号：US14460564

    申请日：2014-08-15

    Applicant: ROHTO PHARMACEUTICAL CO., LTD.

    Inventor： Takayuki MIYANO ,  Takahiro KUROSE ,  Mariyo KATO ,  Yoshihiro TAKAI

    IPC: A61K31/121

    CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

    Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.

    Abstract translation: （a）是（5E，9E，13E）ger anyl ger anyl anyl one one one and and ger ger ger ger ger ger ger ger ger ger ger An An An An An An An An ger ger％％％％％％％％％％％％％％％％％％％％％％％％％％ （5E，9E，13E） - ger ger ger ger anyl anyl anyl，，，，ger ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably 促进生存。 因此，该组合物显示出预防，改善或治疗各种视网膜疾病的显着效果。 此外，组合物在储存期间几乎不变成白色混浊。

Patent Agency Ranking